Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +3.00p +3.92% 79.50p 78.00p 81.00p 80.00p 76.50p 76.50p 256,595 12:20:57
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -1.9 -2.3 - 68.00

OptiBiotix Health PLC Investor evening

02/05/2019 7:00am

RNS Non-Regulatory


TIDMOPTI

OptiBiotix Health PLC

02 May 2019

OptiBiotix Health plc

("OptiBiotix" or "the Company")

Investor evening

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products to tackle obesity, high cholesterol and diabetes, announces that Stephen O'Hara, CEO of Optibiotix, will be presenting at an investor evening hosted by Turner Pope Investments Ltd ("TPI") on Monday, 13 May 2019. The event will be held in the City of London and will commence at 5pm.

To register your interest and obtain further details, please contact TPI on info@turnerpope.com or call 0203 621 4124.

No new material or trading information will be provided.

 
 OptiBiotix Health plc                               www.optibiotix.com 
 Stephen O'Hara, Chief Executive             Contact via Walbrook below 
 
 Walbrook PR Ltd        Tel: 020 7933 8780 or optibiotix@walbrookpr.com 
 Anna Dunphy                                         Mob: 07876 741 001 
 
 

About OptiBiotix Health PLC - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRASSSFSFFUSELI

(END) Dow Jones Newswires

May 02, 2019 02:00 ET (06:00 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart
Your Recent History
LSE
OPTI
Optibiotix..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190627 03:07:33